Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
18
ENLV Quote, Financials, Valuation and Earnings
Last price:
$0.74
Seasonality move
:
5.29%
Day range:
$0.74 - $0.82
52-week range:
$0.74 - $2.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.07x
Volume:
864.2K
Avg. volume:
7.9M
1-year change:
-37.15%
Market cap:
$18.8M
Revenue:
--
EPS (TTM):
-$0.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
-- | -$0.12 | -- | -1.88% | $7.00 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
$0.77 | $7.00 | $18.8M | -- | $0.00 | 0% | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.18 | $2.50 | $2.8M | -- | $0.00 | 0% | 1.01x |
|
CGEN
Compugen Ltd.
|
$1.54 | $6.25 | $144M | 55.83x | $0.00 | 0% | 20.58x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
3.86% | 1.059 | 2.77% | 6.04x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
-$81K | -$2.6M | -57.56% | -59.16% | -- | -$2.3M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Enlivex Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns ENLV or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of --. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About ENLV or CANF?
Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 805.56%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1702.55%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Enlivex Therapeutics Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Enlivex Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is ENLV or CANF More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock ENLV or CANF?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or CANF?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 1.01x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M CANFCan-Fite BioPharma Ltd.1.01x -- -- --
-
Which has Higher Returns ENLV or CGEN?
Compugen Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -369.06%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About ENLV or CGEN?
Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 805.56%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 305.84%. Given that Enlivex Therapeutics Ltd. has higher upside potential than Compugen Ltd., analysts believe Enlivex Therapeutics Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 CGENCompugen Ltd.4 0 0 -
Is ENLV or CGEN More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock ENLV or CGEN?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or CGEN?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Compugen Ltd.'s net income of -$7M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 20.58x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M CGENCompugen Ltd.20.58x 55.83x $1.9M -$7M
-
Which has Higher Returns ENLV or NSRX?
Nasus Pharma has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of --. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M NSRXNasus Pharma-- -- -- -
What do Analysts Say About ENLV or NSRX?
Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 805.56%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Enlivex Therapeutics Ltd. has higher upside potential than Nasus Pharma, analysts believe Enlivex Therapeutics Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 NSRXNasus Pharma0 0 0 -
Is ENLV or NSRX More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENLV or NSRX?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or NSRX?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are larger than Nasus Pharma quarterly revenues of --. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Nasus Pharma's net income of --. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns ENLV or PHGE?
BiomX, Inc. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of --. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About ENLV or PHGE?
Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 805.56%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than Enlivex Therapeutics Ltd., analysts believe BiomX, Inc. is more attractive than Enlivex Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 PHGEBiomX, Inc.1 0 0 -
Is ENLV or PHGE More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock ENLV or PHGE?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or PHGE?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 0.32% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.33% over the past day.
Buy
66
ASTS alert for Dec 26
AST Spacemobile, Inc. [ASTS] is down 7.39% over the past day.
